Author: Shereen, Muhammad Adnan; Khan, Suliman; Kazmi, Abeer; Bashir, Nadia; Siddique, Rabeea
Title: COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses Document date: 2020_3_16
ID: 1mjaycee_14
Snippet: Initially, interferons-a nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49, 51, 52] , however, only remdesivir has shown promising impact against the virus [53] . Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46, 50, 52] . Various other anti-virals are currently being eva.....
Document: Initially, interferons-a nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49, 51, 52] , however, only remdesivir has shown promising impact against the virus [53] . Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46, 50, 52] . Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46, 48, 50, 52] . Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46] . Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54] . In a recent study, it was identified that monoclonal antibody (CR3022) bindswith the spike RBD of SARS-CoV-2. This is likely due to the antibody's epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of -COVID-19 infection [55] . Subgroup clusters are labeled as 1a and 1b for the Alphacoronavirus and 2a, 2b, 2c, and 2d for the Betacoronavirus. This tree is based on the published trees of Coronavirinae [3, 41] and reconstructed with sequences of the complete RNA-dependent RNA polymerase-coding region of the representative novel coronaviruses (maximum likelihood method using MEGA 7.2 software). severe acute respiratory syndrome coronavirus (SARS-CoV); SARS-related coronavirus (SARSr-CoV); the Middle East respiratory syndrome coronavirus (MERS-CoV); porcine enteric diarrhea virus (PEDV); Wuhan seafood market pneumonia (Wuhan-Hu-1). Bat CoV RaTG13 Showed high sequence identity to SARS-CoV-2 [42] . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Search related documents:
Co phrase search for related documents- anti viral and blood plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- anti viral and broad spectrum: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- anti viral and broad spectrum antibiotic: 1, 2, 3
- anti viral and chinese medicine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- anti viral and clinical isolate: 1, 2, 3, 4
- anti viral and high sequence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- anti viral and high sequence identity: 1
- anti viral and infected patient: 1, 2, 3, 4, 5, 6
- anti viral and infection evaluate: 1, 2, 3, 4, 5
- anti viral and interferon beta: 1, 2, 3, 4
- anti viral and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- anti viral and mouse human: 1, 2, 3, 4, 5, 6, 7
- anti viral and neutralize antibody: 1
- anti viral and patient infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- anti viral and positive result: 1, 2, 3, 4, 5, 6, 7
- anti viral and rapid recovery: 1, 2, 3, 4
- anti viral and recent study: 1, 2, 3, 4, 5, 6
- anti viral and receptor bind: 1, 2, 3, 4, 5, 6, 7
- anti viral and SARS induced infection: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date